European Coalition of Positive People

Email

office@ecpp.co.uk

Phone

T: 020 7401 9942

Web

http://www.ecpp.co.uk/

Address

2 Whitehorse Mews, Westminster Bridge Road, London SE1 7QD United Kingdom
About European Coalition of Positive People

ECPP is a London based international HIV/AIDS and Hepatitis C patient organisation working in Europe and Malawi, promoting patient involvement in the development of public policy, delivery and monitoring of services.

Mission

To become a European1 organisation of positive people which will advocate and campaign for our human and civil rights, offer peer support, challenge misinformation and prejudice, while galvanising the diverse, affected communities into action, ensuring access to effective treatments, services and promoting healthy living.

1 Defined in this instance to include the member states of the EU, applicant states and Eastern Europe.

Values

Our ethos is one of self-help. We believe that people living with and/or affected by HIV, Hepatitis C and Tuberculosis should be central to the relevant debates about health and social policy. People have the right to information, backup and role models, and can then deal effectively with the world on their own or with each other's support.

The organisation must be run by, controlled by and represented by a majority of positive people. All member organisations must be as well.

Aims & Objectives

  • To provide a means by which people living with and/or affected by HIV, Hepatitis C, and Tuberculosis have a voice.
  • To empower people living with, and/or affected by HIV, Hepatitis C, and Tuberculosis to access information and resources they need to improve the social and economic welfare of their communities.
  • To campaign and advocate for the interests of people living with and/or affected by HIV, Hepatitis C and Tuberculosis, challenging that which adversely affects their welfare.
  • To work in partnership with other stakeholders to influence governmental policy in such areas as human, civil and disability rights, immigration & migration, access to health care, treatments, standards of care, and social policy.
  • To promote user involvement at all levels in the development of public policy and the planning, delivery and monitoring of services.
  • To influence the regulatory authorities, the pharmaceutical industry and medical treatment system, on such issues, as biotechnology, drug trials, drug development, drugs access, pricing, etc.
  • To encourage and assist in the development of local & national groups of positive people.
  • To strengthen and further develop the Coalition to enable it to achieve its mission.

Issues of concern

  • Access to effective treatments both in Europe and internationally
  • Clinical Trials.
  • Biotechnology, Bioethics and genetic engineering. Stem Cell Research.
  • Pharmaceutical drug pricing, differential pricing, parallel trading & patent protection.
  • Community empowerment and support especially in the developing world.
  • Standards of care and information to patients.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close